ATE398633T1 - Neovaskulär gerichtete immunkonjugate - Google Patents

Neovaskulär gerichtete immunkonjugate

Info

Publication number
ATE398633T1
ATE398633T1 AT00941443T AT00941443T ATE398633T1 AT E398633 T1 ATE398633 T1 AT E398633T1 AT 00941443 T AT00941443 T AT 00941443T AT 00941443 T AT00941443 T AT 00941443T AT E398633 T1 ATE398633 T1 AT E398633T1
Authority
AT
Austria
Prior art keywords
immunoconjugates
alanine
neovascular
factor vii
effector domain
Prior art date
Application number
AT00941443T
Other languages
English (en)
Inventor
Alan Garen
Zhiwei Hu
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of ATE398633T1 publication Critical patent/ATE398633T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
AT00941443T 1999-07-01 2000-06-14 Neovaskulär gerichtete immunkonjugate ATE398633T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14216199P 1999-07-01 1999-07-01

Publications (1)

Publication Number Publication Date
ATE398633T1 true ATE398633T1 (de) 2008-07-15

Family

ID=22498780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941443T ATE398633T1 (de) 1999-07-01 2000-06-14 Neovaskulär gerichtete immunkonjugate

Country Status (11)

Country Link
EP (1) EP1198479B1 (de)
JP (2) JP2003504315A (de)
AT (1) ATE398633T1 (de)
AU (1) AU775621B2 (de)
CA (1) CA2377381C (de)
CY (1) CY1110394T1 (de)
DE (1) DE60039240D1 (de)
DK (1) DK1198479T3 (de)
ES (1) ES2307517T3 (de)
PT (1) PT1198479E (de)
WO (1) WO2001002439A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
AU2003208839A1 (en) * 2002-02-13 2003-09-04 Micromet Ag De-immunized (poly)peptide constructs
AU2003220091B2 (en) * 2002-03-08 2006-02-16 Emory University Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
JP2005538936A (ja) * 2002-03-12 2005-12-22 ノボ　ノルディスク　アクティーゼルスカブ 二量体のｔｆアンタゴニスト
WO2004006962A2 (en) * 2002-07-12 2004-01-22 Novo Nordisk A/S A tissue factor binding immunoconjugate comprising factor viia
WO2004007557A2 (en) * 2002-07-12 2004-01-22 Novo Nordisk A/S Tf antagonist
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
DE602004031390D1 (de) * 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
AU2012203896B2 (en) * 2003-05-06 2014-09-25 Bioverativ Therapeutics Inc. Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005025623A2 (en) * 2003-07-28 2005-03-24 Emory University Ef-24-factor vii conjugates
CA2546580A1 (en) * 2003-11-18 2005-06-09 Iconic Therapeutics, Inc. Homogeneous preparations of chimeric proteins
JP2009203161A (ja) * 2006-06-05 2009-09-10 Mebiopharm Co Ltd リウマチ治療薬
AU2011274423B2 (en) * 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
ES2856968T3 (es) 2016-01-15 2021-09-28 Rigshospitalet Adquisición de imágenes de TEP cuantitativas de la expresión de factor tisular usando factor VII inhibido en el punto activo y marcado con 18F
US20190153119A1 (en) * 2016-04-14 2019-05-23 Iconic Therapeutics, Inc. Compositions and methods for treating disorders associated with neovascularization
US20190358351A1 (en) 2016-11-17 2019-11-28 Minerva Imaging Aps 177-lu labeled active site inhibited factor vii
CA3056396A1 (en) * 2017-03-14 2018-09-20 Ohio State Innovation Foundation Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates
CN111263640A (zh) * 2017-09-27 2020-06-09 俄亥俄州创新基金会 组织因子靶向car-nk和car-t细胞疗法
WO2021030787A1 (en) * 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
ES2193143T3 (es) * 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
DE69519929T2 (de) * 1994-07-11 2001-05-23 Univ Texas Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
IL130908A0 (en) * 1997-01-22 2001-01-28 Univ Texas Tissue-factor (tf) compositions for coagulation and tumor treatment

Also Published As

Publication number Publication date
ES2307517T3 (es) 2008-12-01
WO2001002439A1 (en) 2001-01-11
CY1110394T1 (el) 2015-04-29
EP1198479A4 (de) 2004-10-20
DE60039240D1 (de) 2008-07-31
EP1198479B1 (de) 2008-06-18
JP2003504315A (ja) 2003-02-04
AU775621B2 (en) 2004-08-05
JP5745486B2 (ja) 2015-07-08
JP2012255032A (ja) 2012-12-27
EP1198479A1 (de) 2002-04-24
DK1198479T3 (da) 2008-10-13
AU5614900A (en) 2001-01-22
PT1198479E (pt) 2008-08-12
CA2377381A1 (en) 2001-01-11
CA2377381C (en) 2013-06-11

Similar Documents

Publication Publication Date Title
CY1110394T1 (el) Ανοσοσυζευγματα νεοαγγειακης στοχευσης
ES2224099T3 (es) Inmunotoxinas dirigidas contra antigenos de superficies relacionados con c-erbb-2 (her-2/neu).
Govindan et al. Designing immunoconjugates for cancer therapy
ATE347378T1 (de) Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
SA112330402B1 (ar) اتحادات جسم مضاد- عقار
WO2004032828A3 (en) Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
HK1155070A1 (en) Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders -cd70 -
EP2841103A1 (de) Dr5-liganden-arzneimittelkonjugate
JPH06509563A (ja) 炎症性関節炎の治療用の表皮細胞成長因子受容体を標的とする分子
DE69530109D1 (de) Zusammensetzung für behandlung von maligner tumore und ihre metastase
Muñoz et al. In vitro and in vivo effects of an anti-mouse endoglin (CD105)–immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours
KR20200135841A (ko) 고형 종양을 치료하기 위한 튜불린 교란제들을 포함하는 항체 약물 접합체들의 용도
US5690935A (en) Biotherapy of cancer by targeting TP-3/P80
CA2366713A1 (en) Antibody and chemokine constructs and their use in the treatment of autoimmune diseases
CN116669772A (zh) Gpc3结合剂、其缀合物以及使用它们的方法
Rathore et al. Generation of active immunotoxins containing recombinant restrictocin
WO2004007557A3 (en) Tf antagonist
WO1990011779A1 (en) Heteroconjugates
Maiti et al. Tolerogenic conjugates of xenogeneic monoclonal antibodies with monomethoxypolyethylene glycol. I. Induction of long‐lasting tolerance to xenogeneic monoclonal antibodies
WO2022268050A1 (zh) 一种药物组合及其用途
Morgan Jr et al. Preclinical and clinical evaluation of a monoclonal antibody to a human melanoma-associated antigen
Engert et al. Experimental therapy in Hodgkin's disease
Hertler et al. Immunotoxins in the therapy of leukemias and lymphomas
WO1994002174A1 (en) Immunocomplex
陈东泉 et al. POTENTIAL FOR TARGETING HEPATOMA WITH ANTI-FERRITIN IgG-DAUNOMYCIN IMMUNOCONJUGATE

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1198479

Country of ref document: EP